AIT Therapeutics Announces the Last Patient Has Completed Dosing in its Phase 2 NO-NTM Clinical Trial for Patients Suffering from Nontuberculous Mycobacteria (NTM) Abscessus

Oct 23, 2017 8:30am EDT

AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Treating Infections Caused by Nontuberculous Mycobacteria (NTM)

Oct 03, 2017 8:00am EDT

AIT Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Sep 20, 2017 8:00am EDT

AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown to be Safe and Effective in the Compassionate Use Setting in Cystic Fibrosis Patients with Non-tuberculous Mycobacteria (NTM) Infection

Sep 13, 2017 8:30am EDT

AIT Therapeutics Reports Second Quarter 2017 Financial Results

Aug 11, 2017 9:00am EDT

AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)

Aug 07, 2017 9:00am EDT

AIT Therapeutics to Report Second Quarter Financial Results on Friday, August 11

Jul 27, 2017 4:15pm EDT

AIT Therapeutics to Participate in the JMP Securities Life Science Conference

Jun 15, 2017 4:15pm EDT

AIT Therapeutics Announces Appointment of Steve Lisi as Chief Executive Officer

Jun 14, 2017 8:00am EDT

AIT Therapeutics Inc. Raises Gross Proceeds of $10.9 Million and Completes Reverse Merger

Apr 04, 2017 4:01pm EDT